Currently out of the existing stock ratings of Constantine Davides, 65 are a BUY (95.59%), 3 are a HOLD (4.41%).

Constantine Davides

Work Performance Price Targets & Ratings Chart

Analyst Constantine Davides, carries an average stock price target met ratio of 32.86% that have a potential upside of 43.36% achieved within 98 days. Previously, Constantine Davides worked at BENCHMARK.

Constantine Davides’s has documented 130 price targets and ratings displayed on 25 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on PRVA, Privia Health Group at 28-Feb-2025.

Wall Street Analyst Constantine Davides

Analyst best performing recommendations are on ISPC (ISPECIMEN).
The best stock recommendation documented was for ISPC (ISPECIMEN) at 11/23/2021. The price target of $12 was fulfilled within 1 day with a profit of $1.19 (9.02%) receiving and performance score of 90.22.

Average potential price target upside

of $20.1 (60.84%) on LGVN (LONGEVERON LLC).
of $19.5 (23.42%) on HQY (HEALTHEQUITY).
of $3.22 (71.12%) on OPRX (OPTIMIZERX CORP).

ACER Acer Therapeutics BIVI Biovie ACST Acasti Pharma ELMD Electromed HCTI Healthcare Triangle HCWB HCW Biologics HOTH Hoth Therapeutics INVA Innoviva ISPC iSpecimen KTTA Pasithea Therapeutics Corp LGVN Longeveron LLC NMRD Nemaura Medical NNVC NanoViricides MEDS Trxade Group AGL agilon health AMN AMN Healthcare Services CCRN Cross Country Healthcare CERT Certara EVH Evolent Health HQY HealthEquity HSTM HealthStream OPCH Option Care Health OPRX OPTIMIZERx Corp PGNY Progyny PRVA Privia Health Group

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Jonathan Aschoff (ROTH MKM)